• letlifehappen's Avatar

    letlifehappen posted a blog post

    By: Danielle Ternyila From: targetedonc.com Patients with advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC) can now be treated with the FDA-approved combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) in the frontline setting, based on data from the phase III IMpassion130 trial (NCT02425891). According to Elizabeth Mittendorf, MD, PhD, this is a monumental improvement for the treatment of patients with ...
    The post Immunotherapeutic Agents Expand Treatment Landscape for Triple-Negative Breast Cancer appeared first on Let Life Happen.